Robbins LLP Urges HUMA Stockholders with Large Losses to Contact the Firm for Information About the Humacyte, Inc. Class Action Lawsuit

Core Viewpoint - Robbins LLP has filed a class action on behalf of investors who purchased Humacyte, Inc. securities between May 10, 2024, and October 17, 2024, alleging that the company misled investors regarding its manufacturing practices and the status of its Biologic License Application (BLA) for its acellular tissue engineered vessel [1][2][3]. Group 1: Allegations and Impact - Humacyte is engaged in the development of Acellular Tissue Engineered Vessel (ATEV), a lab-grown blood vessel implant [2]. - On August 9, 2024, Humacyte announced that the FDA required additional time to review its BLA, leading to a stock price decline of $1.29, or 16.4$6.62 per share on August 12, 2024 [2]. - On October 17, 2024, the FDA issued a Form 483 revealing violations at Humacyte's Durham facility, including lack of microbial quality assurance and inadequate quality oversight, causing the stock price to drop by $0.95, or 16.35$4.86 per share [2][3]. Group 2: Disclosure Failures - The complaint alleges that Humacyte failed to disclose that its Durham facility did not comply with good manufacturing practices, which included quality assurance and microbial testing [3]. - It is claimed that the company did not inform investors that the FDA's review of the BLA would be delayed due to the need for remediation of these deficiencies [3]. - The allegations suggest that there was a substantial risk to the FDA approval of ATEV for vascular trauma as a result of these undisclosed issues [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their applications by January 17, 2025 [4]. - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. - The firm has a history of recovering over $1 billion for shareholders and is recognized for its commitment to shareholder rights litigation [5].